News | November 20, 2014

Oxford University Study at AHA Shows Extent of Vascular Damage Caused by Smoking

The researchers found that smokers were 12 times more likely than non-smokers to develop an abdominal aortic aneurism

Oxford clinical study, American Heart Association, abdominal aortic aneurism

Photo courtesy of Portable Networks Graphics


November 20, 2014 — Oxford University researchers presented data that reveal the extent to which smoking causes silent but deadly damage to health at the annual scientific meeting of the American Heart Association (AHA).

Working with Life Line Screening’s database of several million U.S. adults, Oxford researchers looked at people without symptoms who attended the company’s screening service. The researchers found that smokers were 12 times more likely than non-smokers to develop an abdominal aortic aneurism.

They also found that rates of aortic aneurysms were 12 times higher, leg circulation problems seven times higher and carotid artery narrowing five times higher in current smokers compared to those who have never smoked. 

“Smokers are much more likely to develop life-threatening vascular problems,” said Richard Bulbulia, M.D., who led the study.

The researchers used screening data from 3.1 million U.S. adults who underwent four non-invasive procedures: ultrasound of the carotid artery, ultrasound of the aorta, an ECG to help determine stroke risk and blood pressure in the arms and legs to assess circulation. The results are being presented today at the AHA Annual Meeting in Chicago and show the importance of cigarette smoking as a risk factor for these asymptomatic, silent conditions.

The work will also help determine the importance of high cholesterol, high blood pressure and obesity for these ‘silent’ vascular conditions, helping to prevent significant disease and premature death from vascular disease.

This work is funded by a Henry Goodger Fellowship, and CTSU receives core funding from the British Heart Foundation, UK Medical Research Council and Cancer Research UK.

For more information: www.ctsu.ox.ac.uk


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now